STEMdiff™ Trilineage Differentiation Kit
Functional assay kit to assess pluripotency by directed differentiation of human ES and iPS cells to all three germ layers
-
STEMdiff™ Trilineage Differentiation Kit -
Label for STEMdiff™ Trilineage Differentiation Kit -
Label for STEMdiff™ Trilineage Differentiation Kit -
Label for STEMdiff™ Trilineage Differentiation Kit
More Views
Required Products
-
Gentle Cell Dissociation Reagent
Enzyme-free cell dissociation reagent -
Cell detachment solution -
RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2 -
cGMP, feeder-free maintenance medium for human ES and iPS cells
Overview
The STEMdiff™ Trilineage Differentiation Kit provides a simple culture assay to functionally validate the ability of new or established human embryonic stem (ES) and induced pluripotent stem (iPS) cell lines to differentiate to the three germ layers: ectoderm, mesoderm, and endoderm. This kit includes specialized, complete media and monolayer-based protocols to perform parallel in vitro directed differentiation experiments for each germ layer, clearly and reproducibly establishing trilineage differentiation potential within one week. STEMdiff™ Trilineage Differentiation Kit is intended to be an endpoint assay and is not optimized for the generation of cells for downstream differentiation or other applications. STEMdiff™ Trilineage Differentiation Kit has been optimized to assess cells maintained in mTeSR™1.
Advantages:
• Reproducible differentiation to all three germ layers across multiple pluripotent cell lines
• Easy-to-interpret assay results
• Complete, defined culture media
• Standardized, one-week protocol
• Easy-to-interpret assay results
• Complete, defined culture media
• Standardized, one-week protocol
Components:
- STEMdiff™ Trilineage Ectoderm Medium, 175 mL
- STEMdiff™ Trilineage Mesoderm Medium, 100 mL
- STEMdiff™ Trilineage Endoderm Medium, 100 mL
Subtype:
Specialized Media
Cell Type:
Pluripotent Stem Cells
Species:
Human
Application:
Cell Culture; Characterization; Differentiation; Functional Assay; Phenotyping
Brand:
STEMdiff
Area of Interest:
Stem Cell Biology
Related Products
-
Anti-Human CD184 (CXCR4) Antibody, Clone 12G5
Mouse monoclonal IgG2a antibody against human, rhesus, cynomolgus CD184 (CXCR4) -
Anti-Human Nestin Antibody, Clone 10C2
Mouse monoclonal IgG1 antibody against human, cynomolgus nestin -
Anti-Human CD56 (NCAM) Antibody, Clone HCD56
Mouse monoclonal IgG1 antibody against human CD56 (NCAM) -
A non-integrating, self-replicating RNA reprogramming vector for generating iPS cells
Scientific Resources
Product Documentation
Document Type
Product Name
Catalog #
Lot #
Language
05230
Component #05231: EXP date June 2020 or later
05230
Component #05231: EXP date May 2020 or earlier
Educational Materials
(24)
Load More Educational Materials
Product Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area
Workflow Stages for
Workflow Stages
Data and Publications
Publications
(3)
Stem cells and development 2017 MAY
Feeder-Free Derivation of Naïve Human Pluripotent Stem Cells.
Abstract
Abstract
Human pluripotent stem cells (HPSCs) cultured in conditions that maintain pluripotency via FGF and TGFβ signaling have been described as being in a primed state. These cells have been shown to exhibit characteristics more closely related to mouse epiblast-derived stem cells than to so called naïve mouse PSCs said to possess a more ground state pluripotency that mimics the early mouse embryo inner cell mass. Initial attempts to create culture conditions favorable for generation of naïve HPSCs from primed HPSCs has required the use of mouse embryonic fibroblasts as a feeder layer to support this transition. A protocol for the routine derivation and maintenance of naïve HPSCs in completely defined conditions is highly desirable for stem cell researchers to enhance the study and clinical translation of naïve HPSCs. Here we describe a standard protocol for transitioning primed HPSCs to a naïve state using commercial RSet media and xeno-free recombinant vitronectin.
Stem cell research 2017
Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene.
Abstract
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) isolated from the whole blood of a 43-year-old male with hypertrophic cardiomyopathy (HCM) who carries the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7). Patient-derived PBMCs were reprogrammed using non-integrative episomal vectors containing reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotent markers, have trilineage differentiation potential, carry the pathogenic MYH7 variant p.Val698Ala, have a normal karyotype and no longer carry the episomal reprogramming vector. This line is useful for studying the link between variants in MYH7 and the pathogenesis of HCM.
Stem cell research 2017
Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy.
Abstract
Abstract
Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) obtained from a 62-year-old female with familial hypertrophic cardiomyopathy (HCM). PBMCs were reprogrammed to a pluripotent state following transfection with non-integrative episomal vectors carrying reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotency markers, possess trilineage differentiation potential, carry rare variants identified in DNA isolated directly from the patient's whole blood, have a normal karyotype and no longer carry episomal vectors for reprogramming. This line is a useful resource for identifying unknown genetic causes of HCM.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.